Cargando…
Indications for Rituximab Use in an Integrated Health Care Delivery System
BACKGROUND: Rituximab is a top-selling biologic that was first approved by the FDA in 1997 for a non-Hodgkin lymphoma orphan indication. It has since been approved for additional orphan indications, with rheumatoid arthritis as the only FDA-approved, nonorphan indication. Evidence suggests that ritu...
Autores principales: | Delate, Thomas, Hansen, Margaret L., Gutierrez, Amarylis C., Le, Kim N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391100/ https://www.ncbi.nlm.nih.gov/pubmed/32584674 http://dx.doi.org/10.18553/jmcp.2020.26.7.832 |
Ejemplares similares
-
Assessment of the rates and characteristics of the short-term supply of medication (Tider) from an integrated healthcare delivery system in the United States
por: Delate, Thomas, et al.
Publicado: (2017) -
Actual Versus Projected Cost Avoidance for Clinical Pharmacy Specialist -Initiated Medication Conversions in a Primary Care Setting in an Integrated Health System
por: Kroner, Beverly A., et al.
Publicado: (2008) -
Operationalizing the Learning Health Care System in an Integrated Delivery System
por: Psek, Wayne A., et al.
Publicado: (2015) -
Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma
por: Harvey, Michael J., et al.
Publicado: (2022) -
Integrated health care delivery
por: Goodwin, Nick
Publicado: (2011)